Vincent Chung, MD
Hematology · Duarte, CANPI 1588771364
Payments from drug & device makers
Across 492 payments — averaging $22,643 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8.1M
- Takeda Pharmaceuticals U.S.A., Inc.$667K
- Roche Products Limited$454K
- Amgen$400K
- Genentech, Inc.$334K
- AstraZeneca$319K
- plus $868K from 20 others
Across 3 payments — averaging $625.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 283 | $8,098,541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $666,838 |
| Roche Products Limited | 11 | $453,804 |
| Amgen | 10 | $400,464 |
| Genentech, Inc. | 19 | $333,565 |
| AstraZeneca | 11 | $319,286 |
| Ipsen Bioscience Inc. | 10 | $318,164 |
| Biontech SE | 9 | $223,562 |
| Corcept Therapeutics | 9 | $107,288 |
| Sanofi US Services Inc. | 1 | $51,619 |
| Seagen Inc. | 1 | $39,627 |
| Ipsen Biopharmaceuticals, Inc | 32 | $30,694 |
| Astellas Pharma Global Development | 10 | $26,712 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24,175 |
| Halozyme Inc | 8 | $22,860 |
| Bristol Myers Squibb | 11 | $10,497 |
| Coherus Oncology, Inc. | 11 | $9,842 |
| Regeneron | 2 | $2,040 |
| Eisai Inc. | 5 | $282 |
| Caldera Medical, Inc | 1 | $137 |
| Array Biopharma Inc | 4 | $90 |
| Astellas Pharma US Inc | 4 | $78 |
| F. Hoffmann-la Roche AG | 1 | $61 |
| Gilead | 1 | $27 |
| Novartis | 1 | $25 |
| Bayer | 1 | $21 |
How this compares
$11,140,301 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.